IRX5183
J15219
Phase 1 small_molecule terminated
Quick answer
IRX5183 for Acute Myeloid Leukemia (AML) is a Phase 1 program (small_molecule) at IO Biotech with 1 ClinicalTrials.gov record(s).
Program details
- Company
- IO Biotech
- Indication
- Acute Myeloid Leukemia (AML)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- terminated